Search Results 1131-1140 of 15427 for alt

1. Ixabepilone and Temsirolimus in Treating Patients with Solid Tumors that are Metastatic or Cannot ce Removed by Surgery - Mayo Clinic

   ... (ALT) ≤ 3 x ULN or SGOT (AST) ≤ 5 x ULN in the presence of hepatic metastasis; Creatinine ≤ 1.5 x ULN; International normalized ratio (INR) ≤ 1.4 for ...

2. A Study to Evaluate the Safety, Effectiveness, and Tolerability of Latiglutenase to Treat Patients with Well-Controlled Celiac Disease - Mayo Clinic

   Participation eligibility · Elevated liver function tests (Alanine Aminotransferase [ALT], Aspartate Transaminase[AST],Alkaline Phosphatase [Alk Phos], or Gamma- ...

3. Inotuzumab Ozogamicin In Treating Younger Patients With Relapsed Or Refractory CD22 Positive B Acute Lymphoblastic Leukemia - Mayo Clinic

   ... [ALT]) ≤ 3 x ULN for age. Exclusion Criteria: Patients with any prior history of SOS/VOD irrespective of severity. Patients with isolated central nervous ...

4. A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ Capsules in Patients With Advanced Solid Tumors - Mayo Clinic

   Participation eligibility · Bilirubin ≤ 1.5 times upper limit of normal; · AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2.5 times upper limit of normal (if ...

5. A study to test whether survodutide helps people with a liver disease called NASH/MASH who have moderate or advanced liver fibrosis - Mayo Clinic

   Serum AST and/or ALT elevation ≥ 5x ULN;; Platelet count < 140 000/mm3 (< 140 GI/L);; Alkaline phosphatase > 2x ULN;; Abnormal synthetic liver function as ...

6. A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis - Mayo Clinic

   AST and ALT ≤ 3.0 × the upper normal limit (ULN);; Total Bilirubin ≤ 1.5 × ULN (exception: subjects with Gilbert's Syndrome may have a Bilirubin > 1.5 ...

7. Study Of High-dose Spironolactone Vs. Placebo Therapy In Acute Heart Failure - Mayo Clinic

   Severe liver disease (ALT or AST >3 x normal, alkaline phosphatase or bilirubin >2x normal); Active infection (current use of oral or IV antimicrobial agents) ...

8. Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients - Mayo Clinic

   Abnormal liver function tests: Serum aspartate transaminase (AST/SGOT) or alanine transaminase ( ALT/SGPT) 2 x upper limit of normal (ULN). Serum bilirubin ...

9. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

   ... ALT (absence of normal value of ALT within the past year), obesity defined by a BMI ≥ 30, metabolic syndrome (NCEP ATP III definition), type 2 diabetes, or ...

10. Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 - Mayo Clinic

    exception of those with Gilbert syndrome, and AST/ALT within ≤ 3 x upper limit of normal. 8. Renal Function: Creatinine clearance or radioisotope GFR ...